Valuation: Fresenius

Market Cap 2.6TCr 3.04TCr 2.43TCr 2.23TCr 4.19TCr 2,90900Cr 4.27TCr 29TCr 11TCr 1,45800Cr 11TCr 11TCr 4,82600Cr P/E 2026 *
14.2x
P/E 2027 * 12.3x
Enterprise Value 3.64TCr 4.25TCr 3.4TCr 3.12TCr 5.86TCr 4,06800Cr 5.97TCr 40TCr 16TCr 2,03900Cr 16TCr 16TCr 6,74900Cr EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.43x
Free-Float
73%
Yield 2026 *
2.51%
Yield 2027 * 2.69%
Manager TitleAgeSince
Chief Executive Officer 57 01/10/2022
Director of Finance/CFO 46 01/09/2022
Compliance Officer 50 -
Director TitleAgeSince
Director/Board Member 71 20/05/2015
Director/Board Member 65 13/05/2016
Director/Board Member 52 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.06TCr
0.00%-1.41%+32.24%+39.61% 12TCr
-0.19%-1.33%-0.95%+47.83% 8.81TCr
-0.19%+2.23%+30.86%+81.58% 2.67TCr
-0.25%+2.41%-5.63%-8.54% 2.22TCr
+1.52%+2.08%+49.83%+280.57% 2.16TCr
+0.30%-2.29%-9.61%+12.58% 1.42TCr
-0.10%-0.29%-4.93%-8.26% 1.26TCr
-1.15%-2.19%+27.52%+71.99% 1.13TCr
+0.23%-0.92%-18.89%+87.22% 1.01TCr
Average -0.11%+0.22%+11.16%+67.17% 3.63TCr
Weighted average by Cap. +0.13%-0.51%+16.75%+57.50%

Financials

2026 *2027 *
Net sales 2.38TCr 2.78TCr 2.22TCr 2.03TCr 3.82TCr 2,65500Cr 3.9TCr 26TCr 10TCr 1,33100Cr 10TCr 10TCr 4,40600Cr 2.5TCr 2.92TCr 2.33TCr 2.14TCr 4.02TCr 2,79100Cr 4.1TCr 28TCr 11TCr 1,39900Cr 11TCr 11TCr 4,63100Cr
Net income 188.78Cr 220.49Cr 176.14Cr 161.62Cr 303.7Cr 21TCr 309.68Cr 2.09TCr 814.56Cr 11TCr 827.9Cr 809.88Cr 35TCr 215.54Cr 251.75Cr 201.11Cr 184.53Cr 346.75Cr 24TCr 353.58Cr 2.39TCr 930.02Cr 12TCr 945.26Cr 924.69Cr 40TCr
Net Debt 1.04TCr 1.21TCr 967.39Cr 887.67Cr 1.67TCr 1,15900Cr 1.7TCr 11TCr 4.47TCr 58TCr 4.55TCr 4.45TCr 1,92300Cr 957.27Cr 1.12TCr 893.15Cr 819.55Cr 1.54TCr 1,07000Cr 1.57TCr 11TCr 4.13TCr 54TCr 4.2TCr 4.11TCr 1,77500Cr
Logo Fresenius
Fresenius SE & Co. KGaA is a Germany-based healthcare group focused on products and services for the treatment of critically and chronically ill patients. The Company operates through its core businesses, Fresenius Kabi and Fresenius Helios. Fresenius Kabi develops and supplies biopharmaceuticals, clinical nutrition products, medical technologies, intravenously administered generic drugs, and infusion therapies. Fresenius Helios is Europe’s private healthcare provider, operating hospitals, outpatient centers, and other healthcare facilities in Germany, Spain, and Latin America. Fresenius also holds an investment in Fresenius Medical Care, a provider of dialysis products and services for patients with chronic kidney disease.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
46.64EUR
Average target price
55.86EUR
Spread / Average Target
+19.76%

Quarterly revenue - Rate of surprise